Drug Trial News

RSS

Neurological researchers study promising new treatment for deadly brain tumors

A promising new treatment for deadly brain tumors taken orally with minimal side effects is being studied by neurological researchers at Rush University Medical Center, Chicago.

28 Mar 2013

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA, today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.

28 Mar 2013

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute.

28 Mar 2013

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

Neurocrine Biosciences, Inc. today announced that a Phase IIb clinical trial to evaluate elagolix for the treatment of uterine fibroids has been initiated.

27 Mar 2013

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

Soligenix, Inc., a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration has completed its review and cleared the Investigational New Drug application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients.

27 Mar 2013

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Lightlake Therapeutics Inc., an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

27 Mar 2013

Ketamine may help treat severe depression, reduce suicidal urges, UAB researchers say

University of Alabama at Birmingham researchers think ketamine, an anesthesia medication in use since the 1970s, might be a valuable tool in treating severe depression and reducing suicidal urges; they have launched two studies to explore the possibility.

27 Mar 2013

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic azithromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA.

27 Mar 2013

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Among patients with the lung disorder non-cystic fibrosis bronchiectasis, treatment with the antibiotic erythromycin resulted in improvement in symptoms but also increased the risk of antibiotic resistance, according to a study appearing in the March 27 issue of JAMA.

27 Mar 2013

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive data for collagenase clostridium histolyticum or CCH which is being developed for the potential treatment, if approved by the U.S. Food and Drug Administration, of adult patients with adhesive capsulitis, commonly known as Frozen Shoulder syndrome.

26 Mar 2013

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers.

25 Mar 2013

Newly discovered molecule could form the basis of anti-malaria drugs

An international study, involving researchers from Griffith University's Eskitis Institute, has discovered a molecule which could form the basis of powerful new anti-malaria drugs.

25 Mar 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

New imaging agent detects, maps cancers that have reached lymph nodes

Researchers at the University of California, San Diego School of Medicine have shown that a new imaging dye, designed and developed at UC San Diego Moores Cancer Center, is an effective agent in detecting and mapping cancers that have reached the lymph nodes.

21 Mar 2013

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides.

21 Mar 2013

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

An international study involving dermatologists from the Hospital del Mar and Spanish subjects has concluded that a drug normally used to treat severe bronchial asthma caused by allergies (Omalizumab) rapidly eliminates the symptoms of spontaneous chronic urticaria, a development that it is expected will significantly improve the quality of life of chronic urticaria sufferers.

21 Mar 2013

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Chronic hepatitis C infection is one of the most frequent chronic infectious diseases worldwide. The WHO estimates that 150 million people worldwide are chronically infected with the hepatitis C virus (HCV).

20 Mar 2013

Mozambique completes first HIV vaccine clinical trial

Last week, "researchers at Mozambique's Polana Cancio Centre for Research and Public Health completed a trial evaluating the safety of an HIV vaccine candidate," the country's "first HIV vaccine trial," and it "is set to embark on a second, a demonstration of the country's increased HIV research capacity," PlusNews reports.

20 Mar 2013

Drug Trial News

Neurological researchers study promising new treatment for deadly brain tumors

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

Virginia G. Piper Cancer Center Clinical Trials successfully tests cabozantinib

Neurocrine Biosciences starts elagolix Phase IIb clinical trial for treatment of uterine fibroids

FDA clears Soligenix's IND application for SGX942 for treatment of oral mucositis

Lightlake to present Phase II clinical trial results of opioid antagonist nasal spray at APA Annual Meeting

Ketamine may help treat severe depression, reduce suicidal urges, UAB researchers say

Study shows benefit of azithromycin in patients with non-CF bronchiectasis

Erythromycin may provide benefit for patients with non-CF bronchiectasis

Auxilium Pharmaceuticals reports positive results from phase IIa Frozen Shoulder Syndrome clinical trial

BioCryst starts BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

Newly discovered molecule could form the basis of anti-malaria drugs

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

New imaging agent detects, maps cancers that have reached lymph nodes

Researchers complete phase II clinical trial of dasatinib for patients with higher-risk MDS

Study: Drug normally used to treat severe bronchial asthma beneficial for chronic urticaria sufferers

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Mozambique completes first HIV vaccine clinical trial

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News